Introduction
Beta-blocker therapy for patients with chronic heart failure (HF) with reduced ejection fraction was instituted following a series of small mechanistic studies that led to large randomised controlled trials (RCTs) identifying a significant reduction in morbidity and mortality. Their use in symptomatic patients with HF has a class 1A recommendation from both European and American guidelines. 1, 2 Nonetheless, uptake of therapy in clinical practice remains sub-optimal, with those at the greatest risk of death less likely to receive evidence-based therapy. 3 There have also been concerns over treatment efficacy in certain groups, notably patients with atrial fibrillation (AF), women and the elderly. Previous analyses in these important patient subsets have lacked statistical power and further randomised evidence is now unlikely. The Beta-blockers in Heart Failure Collaborative Group was formed to provide definitive answers to a range of unanswered questions relating to HF and beta-blocker therapy, with the aim of optimising use and providing clear guidance on the efficacy and safety of treatment. 4 Chronic HF and AF represent two common conditions that are associated with substantial morbidity and risk of death. 1, 5 Importantly, both are predicted to continue increasing in prevalence 6, 7 , with the incidence of AF expected to double in the next 20 years. 8 Rehospitalisation is seen in over 50% of patients with HF within 6 months 9 and in nearly 40% of AF patients over 12 months. 10 Despite improved medical therapy, HF remains a significant driver of healthcare cost. 11 Those with concomitant AF have even higher mortality and hospital admission rates, regardless of which condition comes first. 12, 13 In addition, the prevalence of AF is closely related to the severity of HF, as determined by NYHA functional class. 14 We sought to examine the efficacy and safety of beta-blockers in patients with HF and concomitant AF by performing an individual patient data (IPD) meta-analysis. Patients with AF are frequently prescribed beta-blockers both for prognostic benefit in HF and heart-rate control, although there is limited and underpowered evidence for efficacy with regards to clinical outcomes. 15 Considered the 'gold-standard' of meta-analysis, IPD allows appropriate examination of sub-groups and the ability to accurately combine original data (thereby improving data quality), perform full time-to-event analyses and generate hazard ratios adjusted for baseline covariates. 16 Assessment of over 18,000 patients randomised to betablockers or placebo permits a robust and adequately-powered analysis of the clinical benefit of beta-blocker therapy in patients with HF and AF, compared to those in sinus rhythm.
A detailed rationale and design paper has previously been published (click here for link to free online publication). 4 To summarise, the Beta-blockers in Heart Failure Collaborative Group (BB-meta-HF) is a multinational effort to combine individual data from the major RCTs investigating the use of beta-blockers in HF. The group consists of the leading investigators of these trials and international experts, with the support of the four pharmaceutical companies that have marketed therapies (AstraZeneca, GlaxoSmithKline, Merck Serono and Menarini). This report was prepared according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines 17 and prospectively registered with Clinicaltrials.gov (NCT0083244) and the PROSPERO database of systematic reviews (CRD42014010012). 18 Eligibility, search strategy and data collection Published or unpublished RCTs were identified through computer aided searches (e.g.
Medline and Current Contents), scrutiny of reference lists of trials, trials registries, meeting abstracts, review articles as well as discussion with group members and pharmaceutical manufacturers. RCTs were included that reported mortality as a primary or composite outcome comparing beta-blockers versus placebo. Only unconfounded head-to-head trials were eligible, with recruitment of >300 patients and planned follow-up of >6 months to make the project technically feasible and clinically-relevant. The search results, individual study demographics and a standardised data request form to obtain IPD from each trial have previously been published. 4 Eleven studies were included that account for 95.7% of eligible recruited participants: the Australia/New Zealand Heart Failure Study (ANZ) 19 , the Beta-Blocker Evaluation Survival Trial (BEST) 20 29 . All included studies had low risk of bias, as determined using the Cochrane Collaborations Risk of Bias Tool. 30 The CHRISTMAS trial was excluded from this analysis as AF was an exclusion criterion.
Data were extracted from original source files and additional follow-up outcomes were available in seven studies. 19-21, 25, 26, 28, 29 The primary outcome was all-cause mortality, including an analysis of total mortality where deaths occurred after early study termination or following a fixed censor point. The mean follow-up period until death or censoring was 1.5 years (SD 1.1) across all studies, which ranged from 0.9 to 5.3 years in the individual trials.
Major secondary outcomes were CV-death, the composite of all-cause mortality and CVhospitalisation, and non-fatal stroke. Hospitalisation outcomes included the time to hospitalisation (any cause), CV-hospitalisation and HF-related hospitalisation, as well as the number and duration of CV/HF hospital admissions. An additional post-hoc defined outcome was the composite of CV-death and HF-related hospitalisation. Drug safety outcomes were focused on discontinuation of study drug therapy due to hypotension, bradycardia, renal impairment, HF-exacerbation or any adverse event.
Atrial fibrillation/flutter
The diagnosis of AF or atrial flutter was determined by the baseline electrocardiogram (ECG). Distinguishing between the two atrial arrhythmias was only possible in two trials. 20, 28 Consistent with clinical expectation, flutter accounted for only 4% of the combined group.
For the purposes of this paper, reference to AF will therefore also include atrial flutter.
Incident AF was defined as AF during follow-up in patients with sinus rhythm at baseline. Follow-up ECGs or adverse event data reflecting new-onset or recurrence of AF were available in all studies, with 862 of 13,946 individual patients (6%) missing data.
Statistical analysis
Data are presented as median and interquartile range (IQR) or percentages. Estimated glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula, normalised to a body surface area of 1.73 m 2 . Three patients had missing event dates and were excluded from outcome analyses. Hospitalisation was not recorded for the MDC trial and NYHA class was not explicitly obtained in the COPERNICUS study. As the amount of missing data for other major variables was low, there was no requirement for imputation of missing values.
All analyses followed the principle of intention to treat. The primary and major secondary outcomes were analysed using a stratified Cox proportional hazards regression model. 31 This is a one-stage fixed effects approach and assumes that all trials are estimating a common treatment effect with baseline hazards that vary across studies. Hazard ratios (HR) and 95% confidence intervals (CI) are presented, along with corresponding p-values, with adjustment for age, gender and baseline left-ventricular ejection fraction (LVEF), heart rate and use of angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB).
Kaplan Meier plots are used to graph the data (pooling data from all trials). As the follow-up periods in individual studies varied, data were censored at 1200 days. Heterogeneity for pooled outcomes was assessed using the chi-squared test and I 2 statistic, with the estimate of heterogeneity taken from the inverse-variance fixed-effects two-stage model. 32 A range of sensitivity analyses were performed, including alternative censor points, separate exclusion of the BEST and CAPRICORN studies, additional baseline adjustment and random effects modelling. 33 Exploratory analyses included a per-protocol analysis assessing patients who remained on study therapy throughout the trial and factors associated with incident AF (using an adjusted logistic regression model as time to diagnosis of AF was not available).
A two-tailed p-value of 0.05 was considered statistically significant. Analyses were performed on Stata Version 11.2 (StataCorp LP, Texas) and R Version 3.0.2 (R Core Team, Vienna).
Results
A total of 18,254 individual participants were assessed, of which 13,946 (76.4%) were in sinus rhythm at baseline and 3,066 (16.8%) in AF. Other rhythms (predominantly paced rhythm or heart block) accounted for 1,124 (6.2%) and 118 patients had a missing or uninterpretable baseline ECG (0.6%). There were minimal differences in baseline characteristics between patients randomised to beta-blockers or placebo in any group (see Supplementary Table 1 ). A comparison of those in sinus rhythm and AF at baseline is presented in Table 1 . The median duration of HF prior to enrolment was 3 years. Compared to those in sinus rhythm, AF patients were 5 years older, with a higher percentage of men.
There were small differences in systolic blood pressure and GFR but LVEF and heart rate were similar. Patients with AF were more symptomatic, with 72% in NYHA class III/IV compared to 62% for those in sinus rhythm. AF patients had more frequent use of diuretics, aldosterone antagonists, digoxin and oral anticoagulants, however 95% in both groups were taking ACEi or ARB at baseline.
Outcomes according to baseline rhythm
Including deaths reported after early or date-based study termination, crude mortality rates were 20.7% in AF patients (633/3,064) and 16.0% in sinus rhythm (2,237/13,945) .
Considering deaths in the study period only, crude mortality rates were 18.1% in AF patients (556/3,064) and 14.5% in sinus rhythm (2,021/13,945). The most common causes of death in both groups were sudden death and death due to heart failure (see Table 2 ). Fatal stroke was relatively uncommon, although as expected more frequent in patients with AF. Table 3 displays pooled hospitalisation data divided into all-cause, CV and HF-related hospital admissions. The total number of hospitalisations and annualised rate per patient were higher in AF patients compared to sinus rhythm for all types, with longer average length of stay (for CV-hospitalisation 11.9 days in AF versus 9.7 days in sinus rhythm).
Efficacy of beta-blocker therapy
A consistent effect of beta-blockers versus placebo was noted across all death and/or hospitalisation outcomes, with benefit demonstrated in sinus rhythm but non-significant differences seen in AF patients (see Table 4 ). P-values for the interaction of treatment efficacy and baseline heart rhythm were significant for each of these outcomes.
Including all reported deaths, the adjusted HR for all-cause mortality in sinus rhythm was 0.73 (95% CI 0.67-0.80) and in patients with AF 0.97 (95% CI 0.83-1.14), with a p-value for interaction of 0.002. Kaplan-Meier survival curves are displayed in Figure 1 . Similar results were seen for CV-deaths or when restricting analysis to deaths during the study period only.
For CV-hospitalisation, the adjusted HR in sinus rhythm was 0.78 (95% CI 0.73-0.83) and in AF 0.91 (95% CI 0.79-1.04), with a p-value for interaction of 0.05; see Figure 2 for Kaplan-Meier event curves. Results were similar for HF-related hospitalisation and the composite clinical outcomes (death or CV-hospitalisation and CV-death or HF-related hospitalisation).
Beta-blocker therapy had no impact on incident non-fatal stroke in either sinus rhythm or AF (see Table 4 ).
Sensitivity and exploratory analyses
Sensitivity analyses for the primary outcome are presented in Supplementary Table 2 . There were no observable effects for additional baseline adjustment, the exclusion of specific trials or the use of different censor points. An alternative analysis method using a two-stage metaanalysis is presented in Figure 3 , which resulted in virtually identical hazard ratios to the onestage approach using both fixed and random effects modelling. Importantly, we identified no heterogeneity between the individual studies for all-cause mortality in patients with AF (I 2 =0%, p=0.65).
An exploratory sub-group analysis was performed within the AF cohort for all-cause mortality, with no significant interactions identified for a range of baseline variables at clinical cut-points, including age, gender, LVEF, NYHA, the control of blood pressure or heart rate, and baseline medical therapy (see Figure 4 ). We also performed a per-protocol assessment for all reported deaths in the AF group. Compared to the intention-to-treat analysis, no difference was identified in the efficacy of beta-blocker therapy in AF patients that remained on therapy (HR 0.84; 95% CI 0.68-1.04), with no significant interaction for discontinuation of study treatment within the AF group (p=0.09).
Incident AF
In patients with sinus rhythm at baseline, 610 (4.7%) developed AF on a subsequent ECG.
The factors independently associated with incident AF in an exploratory analysis were advanced age, male gender, increased BMI and NYHA class III/IV at baseline (see Supplementary Table 3 ). Allocation to beta-blockers was associated with a 33% reduction in the adjusted odds of incident AF (253/6,722 randomised to beta-blockers developed AF, compared to 357/6,362 allocated to placebo).
Study drug dosage, discontinuation, adverse treatment effects and heart rate There were minimal differences in the dose of study drug achieved according to baseline heart rhythm, with overall 84% achieving maximal study dosage in the placebo arm and 73% in those randomised to beta-blockers (see Supplementary Table 4 ). The attained heart rate and change from baseline heart rate were similar in patients with sinus rhythm and AF, although interpretation is confounded by lack of measurement in patients who died prior to the interim study visit (see Supplementary Table 5 ). Rates of study drug discontinuation due to adverse effects were identical in patients allocated to either beta-blockers or placebo (15%). No differences in beta-blocker discontinuation rates were identified comparing sinus rhythm to AF (see Supplementary Table 6 ). The incidence of specific adverse effects causing withdrawal of therapy were low (for example hypotension or bradycardia in 1-2%).
Discussion
This individual patient analysis has investigated the largest cohort of patients with HF due to reduced ejection fraction and AF to-date. Our principal findings are that in contrast to those in sinus rhythm at baseline, patients with HF and AF obtained little or no benefit from beta-blockers, with no significant reduction in all-cause mortality, CV-hospitalisation or composite clinical outcomes compared to placebo. The AF group comprised 3,066 participants with 633 deaths, and although there may still be limited power, this analysis suggests that clinical benefit from beta-blockers is unlikely in patients with combined HF and AF. Patients in AF had higher crude rates of death, more frequent hospitalisation and longer length of stay compared to those in sinus rhythm.
Heart failure and AF are two common conditions that are increasing in prevalence.
Although HF incidence has remained static over the past 25 years 34 , the incidence of AF is increasing 35 and not simply as a function of the ageing population. 36 These two conditions frequently co-exist, with observational data suggesting the presence of AF in 14-50% of patients with symptomatic HF. 14 In HF, atrial remodelling frequently occurs due to sustained increases in pressure, volume and neurohormonal stress, making the development of AF more likely. Similarly, AF can lead to HF both as a direct cause (for example in tachycardiainduced cardiomyopathy) and due to loss of atrioventricular synchrony and impairment in diastolic filling. Heart failure with preserved ejection fraction is as common as the syndrome with reduced LVEF 2 , however no prior trial has examined the impact of pharmacotherapy on diastolic function in patients with AF. However, regardless of the type of HF, the combination with AF is known to adversely affect prognosis 37 and overall represents a massive burden to affected patients, healthcare systems and societies, including substantial healthcare costs. 38 Hospitalisation in HF is the greatest cost contributor 11 and our analysis suggests that AF increases both the risk of hospitalisation and length of stay, reinforcing the importance of finding efficacious therapies in this population.
The lack of prior focus on optimal management of the combination of HF and AF is concerning. Indeed all current guideline recommendations for treatment of HF with reduced LVEF stem from trials predominantly from patients in sinus rhythm. Guidelines from the European Society of Cardiology 1 and the American College of Cardiology Foundation/American Heart Association 2 recommend beta-blocker therapy in patients with HF and AF, based on the efficacy demonstrated from the trials assessed in this paper. Our analysis suggests that the substantial benefit identified in patients with sinus rhythm should not be extrapolated to those with AF. The reason for the lack of efficacy of beta-blockers in patients with AF may be due to several physiological differences. 15 In contrast to sinus rhythm, slower heart rates are not associated with improved survival in AF 39 , although this remains to be adequately tested prospectively. The irregular rhythm in AF is also associated with a detrimental impact on systolic and diastolic cardiac function that is independent of heart rate. 40, 41 There are also structural 42 and cellular 43 consequences of AF that may impact on treatment efficacy. These observations however, do not fully explain why the positive effects of beta-blockers, particularly on myocardial metabolism, do not correspond to prognostic benefit in patients with AF, an anomaly that requires further investigation.
Finally it is important to consider the substantial reduction in hospitalisation and death that was seen in patients with sinus rhythm. Rates of beta-blocker uptake amongst HF patients in clinical practice have been consistently suboptimal 44, 45 and may reflect concern about symptom deterioration after initiation of therapy or the poor generalisability of RCT data to real-world patients. 46 One of the major aims of the Beta-blockers in Heart Failure Collaboration was to improve rates of appropriate beta-blocker use by identifying key patient groups that benefit most from therapy. In this regard, use of beta-blockers in patients with sinus rhythm is strongly recommended and further sub-group analyses in relation to age, gender and diabetes are planned. We also found a reduction in incident AF in those with sinus rhythm treated with beta-blockers. This confirms a previous tabular analysis of betablocker trials in HF 47 and may be an important component of therapeutic benefit in patients with sinus rhythm.
Although we found no evidence that beta-blocker therapy prevents adverse clinical events in patients with HF and AF, it did appear safe with no increase in mortality or hospitalisation observed. This should reassure clinicians, particularly for patients with another indication for beta-blockers, for example acute myocardial infarction or the need for rate control of rapid AF with ongoing symptoms. However, for the primary reason of preventing major adverse cardiovascular outcomes in patients with chronic HF and reduced LVEF, beta-blockers do not appear to be effective in those with AF and should no longer be considered as standard therapy to improve prognosis.
Strengths & Limitations
The strength of our analysis was the use of IPD from large, high quality RCTs, with near-totality of available randomised data. We performed careful and methodical data extraction from original datasets 4 , resulting in improved quality of baseline and outcome data across trials. Although the process of IPD meta-analysis is arduous, there are substantial benefits including the ability to adjust for covariates and produce time-to-event analyses. 16 We were also able to include post-publication data on mortality, explaining the small differences from previously published results in the component RCTs. We confirmed that our conclusions apply across various sub-groups of AF and regardless of meta-analysis methodology. This study provides the most powerful analysis of the efficacy of betablockers in AF ever performed, thereby addressing a key clinical question regarding management of this important group of patients with HF.
As with all meta-analytical techniques, we are limited by the data provided from the individual studies. Although there were missing data for some variables, their impact was minimised by extracting data from source datasets with a published data extraction plan. 4 As previously noted, we were unable to separate those with AF and atrial flutter, however the latter made up only a small proportion of patients. The rate of incident AF was lower than expected from clinical practice and may reflect under-reporting, particularly of paroxysmal AF. Our inability to characterise the type, persistence and duration of AF is a limitation.
Although the validity and reproducibility of LVEF measurement has not been adequately demonstrated in patients with AF, we did not see any difference in the variance of LVEF comparing those with sinus rhythm and AF. Finally, heart failure with preserved ejection fraction accounts for over half of patients with HF, but RCT data on beta-blockers versus placebo in this group are limited. 48 Of the studies included in our analysis, only SENIORS recruited patients with LVEF≥0.50, which accounted for only 1.8% of the pooled dataset.
Hence we are unable to comment on the efficacy of beta-blockers according to rhythm status for patients with HF and preserved LVEF.
Conclusion
In contrast to the beneficial effects noted for patients with sinus rhythm, beta-blocker therapy has no or minimal effect on mortality or cardiovascular hospital admission in patients with heart failure with reduced ejection fraction and atrial fibrillation. Based on our results, we dispute the preferential use of beta-blockers compared with other rate-control medications and emphasise the need for further trials in this common and increasingly important group of patients.
companies that have marketed beta-blockers in heart failure, and the group wishes to extend their gratitude to AstraZeneca, GlaxoSmithKline, Menarini Farmaceutica, and Merck Serono. Note that presented data do not account for differences in baseline demographics between groups. *Average of first five hospitalisations for a CV/HF cause in those patients with at least one admission. Cox regression models in sinus rhythm and AF, adjusted for age, gender, LVEF, heart rate and use of ACEi/ARB, meta-analysed using a fixed-effects approach. Analysis includes all reported deaths, censored at 1200 days. Heterogeneity was significant for sinus rhythm (I 2 =56%, p=0.016) but not for AF (I 2 =0%, p=0.65). 
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